Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,591 | 254 | 1,295 |
| Samples | 1,342 | 215 | 1,097 |
| Peptides | 973 | 150 | 846 |
Function
MTOR · Mechanistic target of rapamycin kinase
The protein encoded by this gene belongs to a family of phosphatidylinositol kinase-related kinases. These kinases mediate cellular responses to stresses such as DNA damage and nutrient deprivation. This kinase is a component of two distinct complexes, mTORC1, which controls protein synthesis, cell growth and proliferation, and mTORC2, which is a regulator of the actin cytoskeleton, and promotes cell survival and cell cycle progression. This protein acts as the target for the cell-cycle arrest and immunosuppressive effects of the FKBP12-rapamycin complex. Inhibitors of mTOR are used in organ transplants as immunosuppressants, and are being evaluated for their therapeutic potential in SARS-CoV-2 infections. Mutations in this gene are associated with Smith-Kingsmore syndrome and somatic focal cortical dysplasia type II. The ANGPTL7 gene is located in an intron of this gene. [provided by RefSeq, Aug 2020].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000361445 | P42345 | 1,585 | 969 |
| ENST00000703140 | A0A8V8TRG9* | 6 | 6 |
Gene Properties
Recurrent Mutations
All 969 amino-acid changes on canonical ENST00000361445 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MTOR · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MTOR – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Endometrial Carcinoma | 20/42 48% | 55/612 9% |
| Hodgkins Lymphoma | 6/16 38% | 6/122 5% |
| Kidney Carcinoma | 11/85 13% | 120/1862 6% |
| Colorectal Carcinoma | 33/143 23% | 184/3239 6% |
| Melanoma | 15/210 7% | 108/1899 6% |
| Burkitts Lymphoma | 4/32 12% | 6/196 3% |
| Gastric Carcinoma | 7/74 9% | 75/1809 4% |
| Germ Cell Tumour | 1/25 4% | 7/169 4% |
| Bladder Carcinoma | 4/58 7% | 35/956 4% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 19/304 6% | 45/1390 3% |
| Other Solid Cancers | 2/94 2% | 55/1515 4% |
| Cervical Carcinoma | 1/35 3% | 15/422 4% |
| Neuroendocrine Tumour | 12/154 8% | 12/577 2% |
| Squamous Cell Lung Carcinoma | 4/57 7% | 20/810 2% |
| Small Cell Lung Carcinoma | 0/9 0% | 20/752 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Other Sarcomas | 6/69 9% | 13/699 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Ovarian Carcinoma | 4/109 4% | 18/998 2% |
| Glioma | 6/52 12% | 35/2127 2% |
| Hepatocellular Carcinoma | 0/46 0% | 42/2210 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Esophageal Carcinoma | 1/23 4% | 13/769 2% |
| Non-Cancerous | 1/104 1% | 14/830 2% |
| Thyroid Gland Carcinoma | 0/45 0% | 26/1592 2% |
| Breast Carcinoma | 4/144 3% | 48/3264 1% |
Mutation Distribution
Where MTOR is mutated · all tissues, split by cell line vs tissue
How many mutations in MTOR were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,591 mutations in MTOR
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|